Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer

September 17, 2021 4:10 pm

— Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed

Patients with relapsed platinum-sensitive ovarian cancer had significant improvement in progression-free survival (PFS) when retreated with the PARP inhibitor olaparib … Read more

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumor cells

August 13, 2021 9:27 pm

A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more

Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?

July 27, 2021 12:44 pm

For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.

The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more

Ceralasertib Olaparib Combo Elicits Promising Activity In Parp Resistant Ovarian Cancer

July 15, 2021 2:43 pm

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

March 22, 2021 4:00 pm

By Chase Doyle

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more

PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status

March 22, 2021 3:00 pm

By Chase Doyle

Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more

PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

March 20, 2021 4:00 pm

Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.

By Charles Bankhead

A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.

Treatment with rucaparib (Rubraca) … Read more

How Biomarker Testing May Help Women Battling Ovarian Cancer

February 18, 2021 6:00 pm

Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.

By

Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of

Read more

PARP Inhibitors Linked With Blood Cancer Risk

December 28, 2020 11:00 am

Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden

By Leah Lawrence

Although rare, poly-ADP ribose polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and occurred even … Read more

SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

November 23, 2020 8:00 pm

By Caroline Hopkins

Using organoids that closely model certain features of ovarian tumors, researchers have identified and tested treatment combinations that may benefit patients, many of whom experience acquired or de novo resistance to PARP inhibitors.

In a study recently … Read more

The Stressful Conclusion of a Clinical Trial

November 9, 2020 9:00 am

By 

When I learned this summer that the clinical trial of the cancer drug that seems to be keeping me alive had unexpectedly shut down, I discovered the murky rules governing drug trials and the stressful confusion they … Read more

ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer

October 28, 2020 4:00 pm

By Andrew D. Bowser

New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommendation may change.

The guidelines, from … Read more

Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer

October 10, 2020 5:00 pm

By Savannah Demko

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

“Preclinical studies suggest the potential for synergy between … Read more

Halting Cancer by Halting DNA Repair

September 25, 2020 11:00 am

By Liam Drew

PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more

Why Some Cancers May Respond Poorly to Key Drugs Discovered

September 22, 2020 4:00 pm

Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University … Read more

Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

September 18, 2020 3:00 pm

Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more

PARP Inhibitors Deemed Too Costly For Across-the-Board Frontline Maintenance in Ovarian Cancer

September 11, 2020 8:00 pm

By Leah Lawrence

A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more

Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer

September 3, 2020 5:00 pm

By Susan Moench, PhD, PA-C

Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more

ASCO Releases New Guidelines on PARP Inhibitor Use for Management of Ovarian Cancer

September 1, 2020 2:00 pm

By Hannah Slater

The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.

The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more